Clay Siegall And His Accomplishments In Cancer Research And Treatment
Seattle Genetics has been at the forefront leading research and fight against cancer. This company was founded by Clay Siegall in 1998. Siegall studied Genetics at George Washington University and zoology in the University of Maryland. His knowledge in cancer treatment has been acquired from the extensive experience gained in various institutions. The work performed by Siegall has had a positive effect globally due to his discovery and cancer therapy inventions.
Dr. Siegall is a pioneer in cancer research and therapeutic drug development programs. As a chief Executive officer in Seattle Genetics Company, he is actively involved to ensure that cancer patients get the best treatment. His passion in this field makes it possible to come up with helpful solutions to curb the illness. The advancements in cancer research and therapies conducted by Seattle Genetics are as a result of his tireless efforts
He has held several senior roles and participate in numerous programs and he was a has been a board member of reputable institutions like Ultragenyx. Previously, he had worked with several other pharmaceuticals and accomplished more successes in leadership positions. The interest and focus in cancer make him carry out more research to aid in reducing suffering encountered by cancer patients.
Due to his efforts, he has earned a number of awards from numerous institutions. He has a serious drive towards cancer treatment and he is actively involved in searching for better cancer therapy. In addition, Clay Siegall is involved in books publications and has written 67 books and holds more than nine patents. He also works on the Editorial Board of three scientific journals and is a member of the Board of Scientific Counselors for the Cancer Treatment Research Foundation.
The main concern that made him engage in major research activities and drug development is the desire to achieve change and alleviate suffering for cancer patients. Seattle Genetics Company in collaboration with another entity has invented antibody-drug conjugates (ADCs), ADCETRIS® which was approved in 2011. A lot of mobilization has been done during his leadership to obtain funds for supporting Seattle Genetics. The funds helped in cancer research, treatment, and drug development using the modern technology.